Medelita is proud to dedicate resources to helping make the world a better place, and we believe in supporting organizations and causes where we have an opportunity to provide tangible benefits to humanity.
You have no items in your shopping cart.
You have no items in your shopping cart.
Medelita is proud to dedicate resources to helping make the world a better place, and we believe in supporting organizations and causes where we have an opportunity to provide tangible benefits to humanity.
With the former administration's policy of Deferred Action for Childhood Arrivals (DACA) on the brink of being repealed, the fate of dozens of doctors-in-training has become unclear.
For low-level problems like bronchitis or urinary tract infections, consumers are more likely to go to the emergency department than to a health clinic located less than a 10-minute drive away, a new study suggests.
Children between 2 and 10 years old who showed up at the ER with public insurance were roughly 20 percent less likely to get admitted during these peak times, according to a recent article published by the Washington Post.
With emergency visits in the U.S. climbing from 115 million in 2005 to 136.3 million in 2016, industry thought leaders have been exploring innovative ways to impact wait times, over crowding, and patient outcomes in emergency departments.
While one in three American children is considered overweight or obese, in Napa County the numbers are mind-boggling.
When it comes to ER overcrowding, hospital staff must balance the impossible: mile-high patient demand with a shortage of physicians and resources.
Breast Cancer Awareness Month marks a time during the year dedicated not only to raising support for those currently fighting cancer, but to promote breast cancer education and prevention for all women.
Targeting transport infrastructure alone is not enough to counteract the negative impact that rising city populations will have on the health of citizens.
Mylan has previously fought against its competitor Teva Pharmaceutical Industries' application to the FDA for approval of its generic EpiPen